Commercially available digital therapeutics (DTx) to treat mental health conditions have been available for over a decade, and the industry has matured substantially. Currently there are thousands of apps for mental health conditions, but only a tiny fraction have chosen to seek regulatory approval and the majority of these are for mental health conditions. Here, we will describe what differentiates digital therapeutics as a class of medicine from these health and wellness apps and provide an overview of the FDA regulatory process and why it’s important. Additionally, we will highlight how digital therapeutics can fill gaps in current treatment paradigms and improve access to care. Finally, audience members will be introduced to the currently available digital therapeutics for ADHD and the data that supports their use.
Learning Objectives:
- Describe what a digital therapeutic is and the FDA regulatory process
- Understand the role digital therapeutics play in the treatment landscape for ADHD
- Identify current digital therapeutics available for patients with ADHD and understand the data that supports their use
Course Features
- Lectures 3
- Quizzes 0
- Duration 72 minutes
- Skill level All levels
- Language English
- Students 27
- Assessments Yes
1 Comment
Interesting webinar. I’m anxious to start using the app for the 99.00/year. I will get in touch with you on LinkedIn about getting in on a trial.
Also do you have a website or email address for The Duke Center for girls and women and ADHD you mentioned earlier in the webinar? Thank you